Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma

Bio-Medicine.Org

COLORADO SPRINGS, Colo., Nov. 12, 2012 /PRNewswire/ -- Cannabis Science, Inc., (CBIS) announces Harvard Medical School releases peer-reviewed study in the Genes & Cancer Journal strongly suggesting that Cannabidiol inhibits growth and induces programmed cell death in Kaposi Sarcoma–associated Herpesvirus-Infected Endothelium. These results from the study at Harvard Medical School support Cannabis Science's approach to the development of CS-TATI-1 to inhibit Kaposi Sarcoma.

Cannabis Science President & CEO, Dr. Robert Melamede states, "We are very encouraged to see the publication of the Harvard study that demonstrates the ability of phytocannabinoids to inhibit Kaposi cells. The Harvard results confirm and emphasize the direction that we have been developing with our initial drug CS-TATI-1 to inhibit Kaposi Sarcoma. Cannabis Science is in the process of submitting several concept sheets to publicly sponsored research programs to move CS-TATI-1 into the clinic as rapidly as possible to the satisfaction of regulatory review for commercialization."

David Purdy, CEO & Founder, World AIDS Institute comments, "This groundbreaking Harvard study on the investigation of the effects on KS by cannabinoids is a fundamental game changer in the treatment of a disease that is one of the top causes of AIDS-related deaths in the world. In fact, there has been a precipitous drop in interest in KS treatment research in the activist world despite the devastation on the African continent caused by this particular AIDS-related malady."

Article is available for review below:

http://gan.sagepub.com/content/early/2012/11/08/1947601912466556.abstract [1]

Abstract:

Kaposi sarcoma is the most common neoplasm caused by Kaposi sarcoma–associated herpes virus (KSHV). It is prevalent among the elderly in the Mediterranean,
'/>"/>

Source URL (retrieved on *09/30/2014 - 8:09am*):
http://www.mdtmag.com/news/2012/11/beth-israel-deaconess-medical-center-harvard-medical-school-study-confirms-cannabis-sciences-approach-development-cs-tati-1-inhibit-kaposi-sarcoma

Links:
[1] http://gan.sagepub.com/content/early/2012/11/08/1947601912466556.abstract